ResearcherHumboldt-Universität zu BerlinActive in the last 2 years
Christopher Neumann
Matched on ORCID iD 0009-0000-9009-8678; OpenAlex author ID A5047418814, A5067995925. Sources: OpenAlex.
Their work
- Papers
- 13 (first author 1, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 28
2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 3 papers
Papers 13
- Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. Co-author DOI 10.1002/cam4.71490↗
- The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic status and therapy-dependent survival in pan… Last author DOI 10.1016/j.ejca.2025.116189↗
- Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer models. Last author DOI 10.1038/s41598-026-47856-1↗
- Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. Last author DOI 10.1186/s12935-025-03969-7↗
- DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites. Co-author DOI 10.1186/s13148-024-01768-x↗
- Cachexia-Affected Survival Based on Inflammatory Parameters Compared to Complex Conventional Nutritional Assessments in Patients with Pancreatic Cancer and Oth… Co-author DOI 10.3390/cancers16061194↗
- 68Ga-labeled fibroblast activation protein inhibitor (FAPI) PET/CT for locally advanced or recurrent pancreatic cancer staging and restaging after chemoradioth… Co-author DOI 10.7150/thno.95329↗
- Inflammation-Based Prognostic Scores in Pancreatic Cancer Patients-A Single-Center Analysis of 1294 Patients within the Last Decade. Co-author DOI 10.3390/cancers15082367↗
- Impact of Smoking, Body Weight, Diabetes, Hypertension and Kidney Dysfunction on Survival in Pancreatic Cancer Patients-A Single Center Analysis of 2323 Patien… Co-author DOI 10.3390/jcm12113656↗
- Influence of Baseline CT Body Composition Parameters on Survival in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm11092356↗
- Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation. Co-author DOI 10.3390/jcm11164905↗
- Cancer Associated Fibroblasts Derived from Pancreatic Adenocarcinoma and Their Role in Cell Migration. First author DOI 10.21873/anticanres.15227↗
- Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2018.09.004↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Uwe Pelzer · 11 shared papers, 2022–2026 · strength 2.08
- Paper Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. DOI 10.1002/cam4.71490↗
- Paper The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic stat… DOI 10.1016/j.ejca.2025.116189↗
- Paper Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer… DOI 10.1038/s41598-026-47856-1↗
- Marcus Bahra · 7 shared papers, 2018–2026 · strength 1.28
- Paper Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. DOI 10.1002/cam4.71490↗
- Paper The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic stat… DOI 10.1016/j.ejca.2025.116189↗
- Paper Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer… DOI 10.1038/s41598-026-47856-1↗
- Matthäus Felsenstein · 6 shared papers, 2021–2026 · strength 1.20
- Paper Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. DOI 10.1002/cam4.71490↗
- Paper The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic stat… DOI 10.1016/j.ejca.2025.116189↗
- Paper Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer… DOI 10.1038/s41598-026-47856-1↗
- Mihnea Paul Dragomir · 5 shared papers, 2024–2026 · strength 1.06
- Paper Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. DOI 10.1002/cam4.71490↗
- Paper The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic stat… DOI 10.1016/j.ejca.2025.116189↗
- Paper Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer… DOI 10.1038/s41598-026-47856-1↗
- François Schneider · 5 shared papers, 2023–2026 · strength 1.00
- Paper Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. DOI 10.1002/cam4.71490↗
- Paper The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic stat… DOI 10.1016/j.ejca.2025.116189↗
- Paper Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. DOI 10.1186/s12935-025-03969-7↗
- Thomas Malinka · 4 shared papers, 2022–2024 · strength 0.67
- Paper Cachexia-Affected Survival Based on Inflammatory Parameters Compared to Complex Conventional Nutritional Assessments in… DOI 10.3390/cancers16061194↗
- Paper Impact of Smoking, Body Weight, Diabetes, Hypertension and Kidney Dysfunction on Survival in Pancreatic Cancer Patients… DOI 10.3390/jcm12113656↗
- Paper Influence of Baseline CT Body Composition Parameters on Survival in Patients with Pancreatic Adenocarcinoma. DOI 10.3390/jcm11092356↗
- Katharina Wansch · 3 shared papers, 2025–2026 · strength 0.67
- Paper Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. DOI 10.1002/cam4.71490↗
- Paper Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer… DOI 10.1038/s41598-026-47856-1↗
- Paper Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. DOI 10.1186/s12935-025-03969-7↗
- Florian Dölvers · 3 shared papers, 2025–2026 · strength 0.67
- Paper Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. DOI 10.1002/cam4.71490↗
- Paper Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer… DOI 10.1038/s41598-026-47856-1↗
- Paper Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. DOI 10.1186/s12935-025-03969-7↗
- Uli Fehrenbach · 2 shared papers, 2022–2023 · strength 0.33
- Pirus Ghadjar · 2 shared papers, 2022–2024 · strength 0.32
- Paper 68Ga-labeled fibroblast activation protein inhibitor (FAPI) PET/CT for locally advanced or recurrent pancreatic cancer … DOI 10.7150/thno.95329↗
- Paper Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The C… DOI 10.3390/jcm11164905↗
- Ellen von Hoerschelmann · 2 shared papers, 2018–2021 · strength 0.22
- Rosa Bianca Schmuck · 2 shared papers, 2018–2021 · strength 0.22
- Johanna Wanda Meyer-Knees · 1 shared paper, 2024 · strength 0.20
- Sebastian Zschaeck · 1 shared paper, 2024 · strength 0.18
- Giulia Metzger · 1 shared paper, 2024 · strength 0.18
- Christian Benzing · 1 shared paper, 2023 · strength 0.17
- Bruno Valentin Sinn · 1 shared paper, 2024 · strength 0.16
- Simon Schallenberg · 1 shared paper, 2024 · strength 0.16
- Teodor G. Calina · 1 shared paper, 2024 · strength 0.16
- Elena Grafenhorst · 1 shared paper, 2024 · strength 0.16
- George A. Călin · 1 shared paper, 2024 · strength 0.16
- Timo Alexander Auer · 1 shared paper, 2022 · strength 0.16
- Nick Lasse Beetz · 1 shared paper, 2022 · strength 0.16
- Jens Stieler · 1 shared paper, 2022 · strength 0.14
- Jana Käthe Striefler · 1 shared paper, 2022 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.